Koa Wealth Management LLC Buys 5,043 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Koa Wealth Management LLC increased its stake in Halozyme Therapeutics by 5.9%, now holding 90,521 shares valued at approximately $4.7 million.
• Research analysts have given Halozyme Therapeutics various ratings, with an average rating of "Hold" and a consensus target price of $73.00.
• In its latest quarterly earnings report, Halozyme Therapeutics exceeded expectations with earnings of $1.54 per share and revenue of $325.72 million, a 40.8% increase year-over-year.

Koa Wealth Management LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,521 shares of the biopharmaceutical company's stock after buying an additional 5,043 shares during the period. Halozyme Therapeutics comprises about 3.7% of Koa Wealth Management LLC's holdings, making the stock its 6th largest position. Koa Wealth Management LLC owned 0.07% of Halozyme Therapeutics worth $4,709,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HALO. Alliancebernstein L.P. increased its holdings in shares of Halozyme Therapeutics by 4.8% in the 1st quarter. Alliancebernstein L.P. now owns 3,215,109 shares of the biopharmaceutical company's stock valued at $205,156,000 after acquiring an additional 146,677 shares during the period. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 4.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,029,160 shares of the biopharmaceutical company's stock valued at $129,478,000 after buying an additional 95,600 shares during the period. TD Asset Management Inc increased its stake in Halozyme Therapeutics by 5.8% in the 1st quarter. TD Asset Management Inc now owns 1,451,842 shares of the biopharmaceutical company's stock valued at $92,642,000 after buying an additional 79,708 shares during the period. Fuller & Thaler Asset Management Inc. increased its position in Halozyme Therapeutics by 27.3% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company's stock worth $72,107,000 after purchasing an additional 242,167 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in shares of Halozyme Therapeutics by 154.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company's stock worth $58,078,000 after purchasing an additional 552,590 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HALO shares. Leerink Partners upgraded shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 target price on the stock in a research report on Tuesday. HC Wainwright restated a "buy" rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday. JMP Securities increased their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley raised their price objective on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, August 18th. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $73.00.

Halozyme Therapeutics Stock Up 0.8%

Shares of Halozyme Therapeutics stock opened at $66.88 on Friday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The business's 50 day simple moving average is $71.48 and its 200-day simple moving average is $62.06. The stock has a market capitalization of $7.82 billion, a price-to-earnings ratio of 15.30, a PEG ratio of 0.35 and a beta of 1.16. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. During the same quarter last year, the company earned $0.91 EPS. The company's revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Activity

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the firm's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. This trade represents a 45.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 108,227 shares of company stock valued at $7,779,595. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.